HCAT earnings call for the period ending December 31, 2020.
N'DJAMENA, Chad (AP) — Chad's military claimed that it has killed some 300 rebels advancing on the capital, N'Djamena, as the government on Monday deployed tanks and other armed vehicles in the city's streets. The death toll given on state television and radio by army spokesman Azim Bermandoa Agouna came a day after the military declared that a rebel column had been “totally decimated” by Chadian soldiers. Confusion and fear mounted in the capital as rumors swirled on social media about whether the Chadian rebels still posed a threat after the weekend clashes.
A labor group that did not secure enough votes from Amazon.com Inc warehouse workers in Alabama to form a union has formally objected to the election results and alleged the online retailer threatened to lay off staff, according to a government filing. Amazon has denied the outcome resulted from intimidation of its employees and said it did not threaten layoffs or a facility closure. Late on Friday, the Retail, Wholesale and Department Store Union (RWDSU) submitted nearly two dozen objections to Amazon's conduct during the election, which it said prevented employees from a "free and uncoerced exercise of choice" on whether to create the company's first-ever U.S. union.
The "Global Embedded Analytics Market Size by Component, by Business Function, by Industry, by Geographic Scope and Forecast" report has been added to ResearchAndMarkets.com's offering.
The COVID-19 pandemic has supercharged the market for short-term vacation rentals, and experts say demand is showing no signs of slowing down.
Get ready, because the Golden Arches are about to shine even brighter thanks to a new collaboration with 21st century global pop icons, BTS.
The global commercial air conditioning system (VRF) market is predicted to undergo huge growth in the coming years. The Asia-Pacific market for commercial air conditioning system (VRF) is projected to dominate the global industry.New York, USA, April 19, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global commercial air conditioning system (VRF) market is anticipated to garner a revenue of $34,619.00 million by 2027, at a CAGR of 13.5% during 2020-2027. COVID-19 Impact on the Global Commercial Air Conditioning System (VRF) Market: The COVID 19 pandemic has had a significant effect on the growth of the global commercial air conditioning system (VRF) market. The introduction of safety measures to control the virus's spread caused organizational problems for industry participants, resulting in a manpower shortage. Along with the instability in the industrial supply chain, the novel coronavirus outbreak triggered a fluctuation in demand for HVAC systems, like VRF systems, as offices and commercial establishments were closed. For More Detail Insights, Download Free Sample Copy of the Report at: https://www.researchdive.com/download-sample/8366 Because of social distancing, suppliers, service providers, and contractors were either not permitted or unwilling to provide installation services, resulting in decreased demand and, as a result, decreased sales volume and revenue for the companies. The effect was then felt all the way up and down the value and supply chain. Market Dynamics Conventional HVAC systems consume approximately 50% of total electricity, placing a financial burden on the user. People are changing their preference toward the VRF system because it is more energy efficient, quieter, and simpler to install and manage. In countries such as the United States, Japan, and China, increasing energy-efficiency consciousness and evolving legislation are expected to boost the growth of the global commercial air conditioning system (VRF) market in the analysis period. Installing a VRF system has a high upfront cost. This system is 15-20% more costly than conventional air conditioning systems, but it is 50% more energy efficient. According to a study conducted by Washington State University, the cost of installing a VRF HVAC system is about USD 18 per square foot served, compared to USD 12 to USD 15 per square foot served for a conventional HVAC system. Thus, the high cost incurred in the installation of VRF systems is anticipated to restrain the growth of the global commercial air conditioning system (VRF) market in the analysis period. The report has segmented the market based on type, component, application, and regional analysis. Heat Pump System Type Sub-Segment is Predicted to Experience the Fastest Growth In the type sub-segment, heat pump system sub-segment is anticipated to experience the fastest growth. In 2019, the heat pump system sub-segment was worth $4,903.40 million, and by 2027, it is expected to be worth $12,470.20. The heat pump system is simple to install and maintain, and it is more energy efficient than a heat recovery system, and hence it is commonly used in residential buildings. Consumers' living conditions in urban areas have improved as a result of an increase in the number of dual-income households; as a result, consumers are spending more on electronic appliances, such as HVAC systems. These factors are anticipated to fuel the growth of the heat pump sub-segment in the analysis period. Connect with Analyst to Reveal How COVID-19 Impacting On Market: https://www.researchdive.com/connect-to-analyst/8366 Outdoor Unit Component Sub-Segment is Anticipated to Garner a Dominant Market Share The outdoor unit sub-segment is anticipated to hold a dominant market share in the global market and it is predicted to garner a revenue of $15,502.4 million in the analysis period. The increasing demand for replacement and retrofitting by countries like U.S., China, Japan, and South Korea. Moreover, consumer preference has changed from conventional HVAC to VRF systems as a result of increased consumer awareness and the introduction of legislation to minimize carbon emissions. These factors are anticipated to fuel the growth of the outdoor unit sub-segment during the analysis period. Commercial Sub-Segment is Anticipated to Garner the Maximum Revenue Share The commercial sub-segment is anticipated to hold a dominant market share in the global market and it is predicted to garner a revenue of $22,204.1 million in the analysis period. This growth can be attributed to the increasing numbers of malls, retail space, and corporate buildings in countries like India, UAE, and China. Mall developers and investors such as Raheja-owned Inorbit Malls, Xander-APG joint venture Virtuous Retail South Asia (VRSA), property developer Prestige Estates Ventures, and Blackstone-owned Nexus Malls, according to the Industry Norm, are looking to double their space in a year or two. North America Region Anticipated to Experience the Fastest Growth The North-America market for commercial air conditioning (VRF) is anticipated to garner a revenue of $1,221.2 million and surge at a CAGR of 17.5% by 2027. The increased adoption of VRF systems by large businesses is anticipated to drive the growth of the market. Growing awareness of the associated benefits of installing VRF systems among commercial consumers and high-end residential buildings, as well as increasing popularity, especially in the United States, are the major factors driving the growth of the commercial air conditioning (VRF) market in this region. Key Players and Business Strategies The report enlists the most significant players of the global commercial air conditioning (VRF) market that include - Carrier Global CorporationIngersoll RandDAIKIN INDUSTRIES, Ltd.Midea GroupJOHNSON CONTROLS INTERNATIONAL PLC.LG ElectronicsMITSUBISHI ELECTRIC CORPORATIONPanasonic CorporationFUJITSUTOSHIBA CORPORATION These industry players are focusing on developing several strategies such as partnerships, mergers and acquisitions, and product launches to promote to the expansion of the market. The report also discusses the other important aspects of the market including financial performance of key players, product portfolio, recent strategic developments, and SWOT analysis. CONTACT: Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) +91-(788)-802-9103 (India) +1-(917)-444-1262 (US) Toll Free: 1-888-961-4454 E-mail: email@example.com Website: https://www.researchdive.com Blog: https://www.researchdive.com/blog/ LinkedIn: https://www.linkedin.com/company/research-dive/ Twitter: https://twitter.com/ResearchDive Facebook: https://www.facebook.com/Research-Dive-1385542314927521
Tucson, Arizona--(Newsfile Corp. - April 19, 2021) - Publicly-held AgriSolar Solutions, Inc. (OTC Pink: AGSO) announces the completion of a change of control with Titan NRG Partners Inc. ("Titan"), in which Titan acquired control through a super-voting preferred class of shares from DTC Group LLC. AGSO's business model shifts to the focus of vertical integration of downstream energy with a synergy of companies, servicing all aspects from the source to the end-user. The officer ...
Opinion of the Management Board of the Joint-stock company "VALMIERAS STIKLA ŠĶIEDRA" on the offer of mandatory share buy-back of the company and its impact on the public interest On April 13, 2021, the Financial and Capital Market Commission decided to permit Duke I S.à r.l. (hereinafter – the Offeror), the shareholder of VALMIERAS STIKLA ŠĶIEDRA, AS (Registration No.: 40003031676, legal address: Cempu iela 13, Valmiera, LV-4201) (hereinafter - the Company), to issue the mandatory share buy-back offer (hereinafter – the Offer) approving the buy-back price of one share 0.54 EUR. The Management Board of the Company finds the Offer to be compliant with the conditions of the Financial Instruments Market Law. The Management Board positively evaluates the Offer considering the fact that the Offeror intends to continue the Company's operations and current business. The Offer itself will not have any impact on employment in the Company and will not affect the Company's general business profile or location. The Management Board of the Company positively assesses the Offeror's intention to carry out financial restructuring of the Company in order to achieve long-term sustainability of the Company's business, which will ensure the Company's ability to develop its business model and provide the Company with necessary investments. About Duke I S.à r.l.Duke I S.à r.l. is a Luxembourg subsidiary of Warwick European Opportunities Holding III LP which is an alternative investment fund managed by Warwick Capital Partners LLP (hereinafter - Warwick). Warwick is a London based investment manager which focuses on European special situations. About VALMIERAS STIKLA ŠĶIEDRA, ASVALMIERAS STIKLA ŠĶIEDRA, AS is one of the leading glass fibre manufacturers in Europe, with more than 55 years of experience in fiberglass production. The Company’s core business areas are glass fibre research, glass fibre product development, production and trade. VALMIERAS STIKLA ŠĶIEDRA, AS together with its UK subsidiary VALMIERA GLASS UK Ltd. is the only group in the world with a vertically integrated structure and a wide range of glass fibre products for the thermal insulation market with a temperature resistance up to 1250°C. Additional information:AS VALMIERAS STIKLA ŠĶIEDRATel.: +371 64202216E-mail: firstname.lastname@example.org
The second film is set to add Dominic West and Hugh Dancy to the cast.
Without health care and employment, and without friendships, Ryan is not living his life as fully as he could, if only society accepted him.
New York, New York--(Newsfile Corp. - April 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more ...
A human rights group appealed to the United Nations on Monday to investigate allegations China's government is committing crimes against humanity in the Xinjiang region. Human Rights Watch cited reports of the mass detention of Muslims, a crackdown on religious practices and other measures against minorities in the northwestern region. It said they amount to crimes against humanity as defined by the treaty that established the International Criminal Court.
Inspur AI Server Wins "Server Solution of the Year" Award in 2021 Data Breakthrough Awards Program
Global building automation system market is expected to witness a significant growth during the forecast period. Hardware sub-segment is expected to be the most lucrative. Commercial sub-segment is estimated to be the most profitable. Security and access control sub-segment is expected to be the most beneficial. North America is expected to dominate the market.New York, USA, April 19, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global building automation system market is estimated to garner a revenue of $142,257.3 million at a CAGR of 9.9% during the forecast period. The inclusive report provides a brief overview of the current scenario of the market including significant aspects of the market such as growth factors, challenges, other market dynamics, restraints and various opportunities during the forecast period. The report also provides all the market figures making it easier and helpful for the new participants to understand the market. Market Dynamics Most of the smart buildings have a building automation system software installed. This system helps in saving energy and electricity. These smart buildings can automatically control the building operations such as air conditioning, ventilation, heating, and security. The increasing demand for energy-efficient and eco-friendly green buildings is predicted to enhance the market growth during the forecast period. For More Detail Insights, Download Free Sample Copy of the Report at: https://www.researchdive.com/download-sample/8372 The main restraint hindering the growth of the market is the high cost of building automation systems. The SMEs and startups of the real estate cannot afford the building automation system software because of its high cost. The adoption of artificial intelligence for fully automated construction process is supposed to create more opportunities for the global building automation system market during the estimated period. Segment-wise Analysis of the Market The report has divided the market into different segments based on component, application, offerings, and regional outlook. Hardware Sub-Segment Expected to Earn the Highest Market Share The hardware sub-segment is predicted to grow with a CAGR of 8.6% in the estimated period. Hardware being an essential component for the setting up of automation system in the building construction process, there is an increase in the demand of hardware in building automation systems. This is the reason behind the growth of the market during the forecast period. Commercial Sub-Segment Estimated to be the Most Profitable Commercial sub-segment is predicted to grow with a CAGR of 8.9% during the forecast period. The main reason behind this growth is the rising usage of building automation system for various security reasons in the commercial sector. Connect with Analyst to Reveal How COVID-19 Impacting On Market: https://www.researchdive.com/connect-to-analyst/8372 Security and Access Control Sub-Segment will be the Most Beneficial The sub-segment is predicted to grow with a CAGR of 8.6% during the forecast period. Security and access control helps to control, manage, and access the security along with the control panels and servers. North America to Dominate the Market The North America regional market is projected to grow with a CAGR of 9.1%. The presence of large number of companies for construction activities in the region is expected to be the biggest driving factor for this growth. Key players of the Market The report includes the most significant players of the market which are - Honeywell International Inc.Robert Bosch GmbHGeneral electricalMitsubishi Electric CorporationABB Ltd.Johnson Controls International PLCSiemens AGHubbell Inc.Schneider Electric SEUnited Technologies Corporation The report also reviews many other important aspects including financial performance of the key players, SWOT analysis, product portfolio, and latest strategic developments. Impact of COVID-19 on the market Due to the temporary slowdown of the construction activities during the nationwide shutdowns, the market has witnessed a negative impact. However, as the pandemic restrictions are cleared, the demand for the building automation systems has increased, indicating a rise in the growth of the market. CONTACT: Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) +91-(788)-802-9103 (India) +1-(917)-444-1262 (US) Toll Free: 1-888-961-4454 E-mail: email@example.com Website: https://www.researchdive.com Blog: https://www.researchdive.com/blog/ LinkedIn: https://www.linkedin.com/company/research-dive/ Twitter: https://twitter.com/ResearchDive Facebook: https://www.facebook.com/Research-Dive-1385542314927521
MADISON, Wis. — Foxconn Technology Group, the world's largest electronics manufacturer, has reached a new deal with reduced tax breaks for its scaled back project in southeast Wisconsin, Gov. Tony Evers and the the company announced on Monday. Details of the new deal were not immediately released. It was scheduled to be approved at a Tuesday meeting of the Wisconsin Economic Development Corp., the state's top jobs agency that previously negotiated the initial deal with Foxconn. The original deal with nearly $4 billion in state and local tax incentives was struck in 2017 by then-Gov. Scott Walker. It was based on Taiwan-based Foxconn's promise to build a massive $10 billion flat screen panel manufacturing facility in Mount Pleasant, near the Illinois border, employing up to 13,000 people. Then-President Donald Trump hailed the project as the “eighth wonder of the world.” But Foxconn, best known for making Apple iPhones, has continually scaled back its plans for the site and missed employment targets that would trigger state tax credits. Evers, who ran against Walker in 2018 as a critic of the deal, said in a statement Monday that the new deal “works for everyone.” Jay Lee, Foxconn's vice chairman, said Foxconn approved the new deal with a desire to lower taxpayer liability in exchange for the flexibility to pursue business opportunities the meet market demand." Foxconn's chairman said last month it was considering making electronic vehicles at the facility. Scott Bauer, The Associated Press
The Labour Party leader was told to leave a pub in Bath by an irate landlord.
The Ingenuity drone completes the first powered, controlled flight by an aircraft on another world.
Fifth Third Bank names Jay Plum head of Mortgage
Amazon (NASDAQ: AMZN) has been a big winner for investors. This growing customer base is helping Amazon cement its lead by attracting lots of third-party merchants. In the fourth quarter, sales of third-party units made up 55% of Amazon's total paid units in its retail business -- the highest level in the company's history.
Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-daily, topical roflumilast foam for the treatment of scalp and body psoriasis and seborrheic dermatitis.WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present new data from three studies evaluating the safety, efficacy, and tolerability of its once-daily, topical roflumilast cream and foam at the American Academy of Dermatology Virtual Meeting Experience (VMX) April 23 - 25, 2021. “Patients suffering from plaque psoriasis, scalp psoriasis, and seborrheic dermatitis have significant unmet needs given the lack of efficacious, safe, tolerable topical options for long-term use,” said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. “We are pleased to share these new data that further reinforce the potential of roflumilast cream and foam in various inflammatory skin diseases. If approved by the FDA, our therapies could change the treatment paradigm for patients and their providers in addressing challenging inflammatory dermatological conditions that can significantly impact quality of life.” The data include positive results from a Phase 2b study of roflumilast foam for the treatment of scalp and body psoriasis, as well as a Phase 2 study of roflumilast foam in patients with seborrheic dermatitis. Two additional poster slide presentations will feature sub-analyses from the previously published Phase 2b study of roflumilast cream in the treatment of chronic, mild-to-severe plaque psoriasis: 1) the correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes, and 2) the treatment of steroid-sensitive areas of the body including the face, neck, and intertriginous areas. Finally, Dr. Kim Papp will present results from a new measurement, PASI-HD, which he developed in conjunction with the Arcutis medical team and which was used in the Phase 2b study of roflumilast cream in plaque psoriasis. In areas where the affected body surface area is low (<10%), PASI-HD better distinguishes disease severity than the traditional Psoriasis Area and Severity Index (PASI), which is a gold standard measure in psoriasis clinical trials. Details of Arcutis’ AAD Virtual Congress presentations include: Late-breaking Oral Presentation (PSO 204): Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-blind, Vehicle-controlled Phase 2b StudyDate: April 24, 2021Poster Presentation Plus Recording (SebDerm 203): Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Randomized, Double-blind, Vehicle-controlled Phase 2 Study Date: April 23, 2021Poster Presentation (PSO 201): Correlation of Itch Response to Roflumilast Cream with Disease Severity and Patient-Reported Outcomes in Patients with Chronic Plaque Psoriasis Date: April 23, 2021Poster Presentation (PSO 201): Roflumilast Cream Significantly Improves Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area InvolvementDate: April 23, 2021Poster Presentation (PSO 201): The PASI-HD Improved Precision in Measuring Disease Severity in Subjects with Mild-to-Moderate Plaque Psoriasis Treated with Roflumilast Cream, a Phosphodiesterase-4 InhibitorDate: April 23, 2021 Roflumilast is a highly potent phosphodiesterase-4 (PDE4) inhibitor in development for plaque psoriasis (PsO). Arcutis is investigating roflumilast as a once-daily, nonsteroidal, topical treatment for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter. Join the conversation with the hashtag #AADVMX2021. About PsoriasisPsoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful. Scalp psoriasis is a manifestation of plaque psoriasis characterized by plaques in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. Patients with scalp psoriasis commonly have plaques on other areas of the body as well. Scalp psoriasis is present in nearly half of Americans with psoriasis. As with psoriatic plaques on other parts of the body, scalp psoriasis is often itchy and sometimes painful. It can also be associated with hair loss. About Seborrheic DermatitisSeborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, or recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. Seborrheic dermatitis occurs most often on the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back. About Topical Roflumilast Cream and FoamRoflumilast Cream and Foam are once-daily, topical formulations of a highly potent and selective PDE4 inhibitor (roflumilast). The foam formulation was developed to treat inflammatory dermatoses in hair-bearing areas of the body, such as the scalp, although it is usable in all areas of the body. Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors for dermatology. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, atopic dermatitis, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis and the systemic treatment of plaque psoriasis. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter. Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Investor and Media Contact:Heather Rowe Armstrongharmstrong@arcutis.com805-418-5006 ext. 740